166 related articles for article (PubMed ID: 19855234)
1. Biochemical testing for neuroendocrine tumors.
Vinik AI; Silva MP; Woltering EA; Go VL; Warner R; Caplin M
Pancreas; 2009 Nov; 38(8):876-89. PubMed ID: 19855234
[TBL] [Abstract][Full Text] [Related]
2. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
5. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
6. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
Modlin IM; Gustafsson BI; Moss SF; Pavel M; Tsolakis AV; Kidd M
Ann Surg Oncol; 2010 Sep; 17(9):2427-43. PubMed ID: 20217257
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
Rorstad O
J Surg Oncol; 2005 Mar; 89(3):151-60. PubMed ID: 15719376
[TBL] [Abstract][Full Text] [Related]
9. [Chromogranin A: a marker of neuroendocrine tumors].
D'Herbomez M; Gouze V
Ann Biol Clin (Paris); 2002; 60(6):641-6. PubMed ID: 12446227
[TBL] [Abstract][Full Text] [Related]
10. [Changes in the concept of neuroendocrine tumor].
Sasano H
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1602-5. PubMed ID: 19838016
[TBL] [Abstract][Full Text] [Related]
11. Management of pancreatic neuroendocrine tumors.
Dabizzi E; Panossian A; Raimondo M
Minerva Gastroenterol Dietol; 2010 Dec; 56(4):467-79. PubMed ID: 21139544
[TBL] [Abstract][Full Text] [Related]
12. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
[TBL] [Abstract][Full Text] [Related]
13. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
14. Bronchopulmonary carcinoid tumors--a significant diagnostic problem.
Kedra P; Jeleń M; Szkudlarek-Gruszczyńska T; Leśkow E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():146-61. PubMed ID: 9337533
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
16. Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors.
Vinik E; Silva MP; Vinik AI
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):97-109, viii. PubMed ID: 21349413
[TBL] [Abstract][Full Text] [Related]
17. Plasma chromogranin a: concern on laboratory investigation.
Wiwanitkit V
Am J Gastroenterol; 2010 Dec; 105(12):2702; author reply 2702. PubMed ID: 21131937
[No Abstract] [Full Text] [Related]
18. Serine protease inhibitor 8 is a novel immunohistochemical marker for neuroendocrine tumors of the pancreas.
de Koning PJ; Bovenschen N; Broekhuizen R; Lips CJ; Kummer JA
Pancreas; 2009 May; 38(4):461-7. PubMed ID: 19188865
[TBL] [Abstract][Full Text] [Related]
19. Laboratory tests for neuroendocrine tumours.
Seregni E; Ferrari L; Stivanello M; Dogliotti L
Q J Nucl Med; 2000 Mar; 44(1):22-41. PubMed ID: 10932599
[TBL] [Abstract][Full Text] [Related]
20. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.
O'Toole D; Grossman A; Gross D; Delle Fave G; Barkmanova J; O'Connor J; Pape UF; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):194-202. PubMed ID: 19713711
[No Abstract] [Full Text] [Related]
[Next] [New Search]
